Literature DB >> 32483737

Natural Killer Cell Immunotherapy for Osteosarcoma.

Brian P Tullius1, Buhvana A Setty1, Dean A Lee2.   

Abstract

Natural killer (NK) cells are lymphocytes of the innate immune system that have the ability to recognize malignant cells through balanced recognition of cell-surface indicators of stress and danger. Once activated through such recognition, NK cells release cytokines and induce target cell lysis through multiple mechanisms. NK cells are increasingly recognized for their role in controlling tumor progression and metastasis and as important mediators of immunotherapeutic modalities such as cytokines, antibodies, immunomodulating drugs, and stem cell transplantation. Recent advances in manipulating NK cell number, function, and genetic modification have caused renewed interest in their potential for adoptive immunotherapies, which are actively being tested in clinical trials. Here, we summarize the evidence for NK cell recognition of osteosarcoma, discuss immune therapies that are directly or indirectly dependent on NK cell function, and describe potential approaches for manipulating NK cell number and function to enhance therapy against osteosarcoma.

Entities:  

Keywords:  Adoptive immunotherapy; Antibody-dependent cell cytotoxicity; Chimeric antigen receptor; Immunomodulating drugs; Innate immunity; Natural killer cell

Mesh:

Year:  2020        PMID: 32483737     DOI: 10.1007/978-3-030-43032-0_12

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  73 in total

Review 1.  Activating and inhibitory receptors of natural killer cells.

Authors:  Hollie J Pegram; Daniel M Andrews; Mark J Smyth; Phillip K Darcy; Michael H Kershaw
Journal:  Immunol Cell Biol       Date:  2010-06-22       Impact factor: 5.126

Review 2.  Natural killer cells: integrating diversity with function.

Authors:  Kuldeep Cheent; Salim I Khakoo
Journal:  Immunology       Date:  2009-04       Impact factor: 7.397

Review 3.  Human natural killer cell development and biology.

Authors:  Sherif S Farag; Michael A Caligiuri
Journal:  Blood Rev       Date:  2005-12-20       Impact factor: 8.250

Review 4.  Natural killer cells in malignant hematology: A primer for the non-immunologist.

Authors:  Geoffrey S Kannan; Arianexys Aquino-Lopez; Dean A Lee
Journal:  Blood Rev       Date:  2016-09-09       Impact factor: 8.250

Review 5.  Cellular therapy: Adoptive immunotherapy with expanded natural killer cells.

Authors:  Dean A Lee
Journal:  Immunol Rev       Date:  2019-07       Impact factor: 12.988

Review 6.  Oncogenic stress sensed by the immune system: role of natural killer cell receptors.

Authors:  David H Raulet; Nadia Guerra
Journal:  Nat Rev Immunol       Date:  2009-08       Impact factor: 53.106

7.  Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation.

Authors:  Karina L McQueen; Kristel M Dorighi; Lisbeth A Guethlein; Ruby Wong; Bharati Sanjanwala; Peter Parham
Journal:  Hum Immunol       Date:  2007-03-12       Impact factor: 2.850

8.  Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients.

Authors:  G Pittari; G Fregni; L Roguet; A Garcia; A-L Vataire; S Wittnebel; S Amsellem; S Chouaib; J-H Bourhis; A Caignard
Journal:  Bone Marrow Transplant       Date:  2009-10-05       Impact factor: 5.483

Review 9.  Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

Authors:  A Moretta; C Bottino; M Vitale; D Pende; C Cantoni; M C Mingari; R Biassoni; L Moretta
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

10.  Interferon Gamma Induces Changes in Natural Killer (NK) Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer Cell Lines.

Authors:  Arianexys Aquino-López; Vladimir V Senyukov; Zlatko Vlasic; Eugenie S Kleinerman; Dean A Lee
Journal:  Front Immunol       Date:  2017-04-06       Impact factor: 7.561

View more
  4 in total

1.  Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma.

Authors:  Xiuxia Lu; Mengmeng Liu; Jing Yang; Yi Que; Xing Zhang
Journal:  Clin Exp Immunol       Date:  2022-08-19       Impact factor: 5.732

Review 2.  Prospects for NK Cell Therapy of Sarcoma.

Authors:  Mieszko Lachota; Marianna Vincenti; Magdalena Winiarska; Kjetil Boye; Radosław Zagożdżon; Karl-Johan Malmberg
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639

Review 3.  Natural Killer and T Cell Infiltration in Canine Osteosarcoma: Clinical Implications and Translational Relevance.

Authors:  Aryana M Razmara; Sean J Judge; Alicia A Gingrich; Sylvia M Cruz; William T N Culp; Michael S Kent; Robert B Rebhun; Robert J Canter
Journal:  Front Vet Sci       Date:  2021-11-16

4.  Development of a Machine Learning-Based Autophagy-Related lncRNA Signature to Improve Prognosis Prediction in Osteosarcoma Patients.

Authors:  Guang-Zhi Zhang; Zuo-Long Wu; Chun-Ying Li; En-Hui Ren; Wen-Hua Yuan; Ya-Jun Deng; Qi-Qi Xie
Journal:  Front Mol Biosci       Date:  2021-05-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.